Recombinant DNA Technology

Abstract

Get full access to this article

View all access options for this article.

References

Black WJ : Drug products of recombinant DNA technology. Am J Hosp Pharm 46:1834-1844,1989

Miller HI , Young FE : The drug approval process at the Food and Drug Administration—New biotechnology as a paradigm of a science-based activist approach. Arch Intern Med 149:655-657, 1989

Sethi ML : Recombinant DNA technology and therapeutic products. Pharm Times 56:122-133, 1990

Anon : Biotechnology medicines in development—90 biotech drugs and 14 vaccines in the pipeline. Washington, DC, Pharmaceutical Manufacturers Association, 1990

Anon : Immunotherapeutics—A new direction in cancer treatment, in Cancer Insights, No. 2. Emeryville, CA, Cetus Corporation, 1989

Garnick RL , Solli NJ , Papa PA : The role of quality control in biotechnology: An analytical perspective . Anal Chem 60:2546-2557,1988

Anicetti VR , Keyt BA , Hancock WS : Purity analysis of protein pharmaceuticals produced by recombinant DNA technology . Trends BioTech 7:342-349, 1989

Donahue RE , Wang EA , Kaufman RJ , et al: Effects of N-linked carbohydrate on the in vivo properties of human GM-CSF. Cold Spring Harbor Symp Quant Biol 51:685-692, 1986

Hotchkiss A. , Refino CJ , Leonard CK , et al: The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Thromb Haemost 60:255-261, 1988

10.

Garabedian HD , Gold HK , Leinbach RC , et al: Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. J Am Coll Cardiol 9:599-607, 1987

11.

Food and Drug Administration : Guidelines for submitting documentation for the stability of human drugs and biologics. February 1987

12.

Geigert J. : Overview of the stability and handling of recombinant protein drugs. J Parenter Sci Technol 43:220-224,1989

13.

Lee CY , Mauro VF , Alexander KS : Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs. Am J Hosp Pharm 47:606-608, 1990

14.

Cossum PA : Pharmacologic basis for the safety assessment of recombinant human proteins . J Am Coll Toxicol 8:1133-1138, 1989

15.

Hill DE : Regulating biotechnology licensed products. J Parenter Sci Tech 43:139-141,1989

16.

Slater M. : Regulatory affairs issues in biotechnology. Drug Info J 22:123-131, 1988

17.

Carter M. : Practical points to consider from the manufacturers' perspective in developing recombinant products. Regul Affairs 1:111-118, 1989

18.

Biosafety Task Force, PDA : Review of biosafety guidelines. J Parenter Sci Tech 43:252-258, 1989

19.

Chang TM , Langer R. , Sparks RE , et al: Drug delivery sytems in biotechnology. Artif Organs 12:248-251,1988 20. Weiner AL : Developing lipid-based vehicles for peptide and protein drugs—Part 1: Selection and analysis issues. BioPharm 27-32,1990

20.

Stein CA , Cohen JS : Oligodeoxynucleotides as inhibitors of gene expression: A review. Cancer Res 48:2659-2668, 1988

21.

Walder J. : Antisense DNA and RNA: Progress and prospects. Genes Dev 2:502-504, 1988

22.

Riordan JR , Rommens JM , Kerem B. , et al: Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 245:1066-1073, 1989

23.

Stewart CF , Fleming RA : Biotechnology products: New opportunities and responsibilities for the pharmacist . Am J Hosp Pharm 46:S4-S8, 1989 (suppl)

24.

Montague MJ : The impact of biotechnology on the practice of pharmacy in the year 2000. Consult Pharm 4:26-30, 1989 (suppl)